Cutler Group LP Halozyme Therapeutics, Inc. Call Options Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2020 Oct 27, 2020	BUY	$25.74 - $29.63 $378,378 - $435,561	14,700 New	14,700 $20,000
Q1 2020 May 07, 2020	SELL	$13.9 - $21.83 $41,700 - $65,489	-3,000 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$14.75 - $17.26 $442,500 - $517,800	-30,000 Reduced 90.91%	3,000 $2,000
Q1 2019 May 10, 2019	BUY	$13.94 - $17.58 $373,592 - $471,143	26,800 Added 432.26%	33,000 $15,000
Q2 2018 Aug 10, 2018	SELL	$16.87 - $20.3 $67,480 - $81,200	-4,000 Reduced 39.22%	6,200 $12,000
Q1 2018 May 11, 2018	SELL	$17.06 - $21.2 $417,969 - $519,400	-24,500 Reduced 70.61%	10,200 $26,000
Q4 2017 Jan 17, 2018	BUY	$16.75 - $20.8 $50,250 - $62,400	3,000 Added 9.46%	34,700 $144,000
Q3 2017 Oct 17, 2017	BUY	$11.76 - $17.4 $372,792 - $551,580	31,700	31,700 $114,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.69B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.